









Markets
/
Stocks
/
nasdaq-nivf
/

NewGenIvf Group Ltd

NIVF

1.925USD

-0.125-6.10%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

72.77KMarket Cap

0.00P/E TTM



NewGenIvf Group Ltd

1.925

-0.125-6.10%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NewGenIvf Group Ltd

Currency: USD Updated: 2026-03-27

Key Insights

NewGenIvf Group Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 66 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is low.Over the past month, multiple analysts have rated it as , with the highest price target at 900.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NewGenIvf Group Ltd's Score

Industry at a Glance

Industry Ranking

66 / 75

Overall Ranking

520 / 4542

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

NewGenIvf Group Ltd Highlights

StrengthsRisks

NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.43M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.53K shares, increasing 43.38% quarter-over-quarter.

Analyst Rating

Based on 0 analysts

Current Rating

900.000

Target Price

+43802.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of NewGenIvf Group Ltd is 5.95, ranking 62 out of 75 in the Healthcare Providers & Services industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.28M, representing a year-over-year decrease of 12.94%, while its net profit experienced a year-over-year decrease of 84822.54%.

Score

Industry at a Glance

Previous score

5.94

Change

0.01



Financials

4.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.51

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.44

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

NewGenIvf Group Ltd's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of NewGenIvf Group Ltd is 7.62, ranking 25 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is 0.00, which is 120225937.50% below the recent high of 961.81 and 30779000.00% above the recent low of -246.23.

Score

Industry at a Glance

Previous score

7.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for NewGenIvf Group Ltd. The Healthcare Providers & Services industry's average is 7.54. The average price target is 75.00, with a high of 75.00 and a low of 75.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of NewGenIvf Group Ltd is 1.02, ranking 75 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 2.96 and the support level at 1.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.02

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.291

Neutral

RSI(14)

36.064

Neutral

STOCH(KDJ)(9,3,3)

46.355

Neutral

ATR(14)

0.284

Low Volatility

CCI(14)

-14.626

Neutral

Williams %R

63.548

Sell

TRIX(12,20)

-2.784

Sell

StochRSI(14)

69.229

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.872

Buy

MA10

1.859

Buy

MA20

2.104

Sell

MA50

3.529

Sell

MA100

10.100

Sell

MA200

85.814

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

HRT Financial LP

-100.00%

JAK Opportunities VI LLC

2.92K

ATW Spac Management LLC

225.00

White Lion Capital LLC

140.00

SBI Securities Co., Ltd.

62.00

BofA Global Research (US)

2.00

National Bank of Canada

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of NewGenIvf Group Ltd is 1.04, ranking 69 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.